BC Week In Review | Sep 1, 2014
Company News

Basilea management update

Basilea Pharmaceutica AG (SIX:BSLN), Basel, Switzerland   Business: Infectious, Dermatology, Cancer   Hired: David Veitch as chief commercial officer of Basilea’s Basilea Pharmaceutica International Ltd. subsidiary, formerly president of European operations at Savient Pharmaceuticals Inc....
BC Week In Review | Jan 20, 2014
Company News

Crealta Pharmaceuticals, Savient deal

Crealta completed its acquisition of Savient's pharmaceutical portfolio, including gout drug Krystexxa pegloticase, for about $120.4 million (see BioCentury, Dec.16, 2013). Crealta Pharmaceuticals LLC , Lake Forest, Ill.   Savient Pharmaceuticals Inc. (OTCQB:SVNTQ), Bridgewater, N.J.  ...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer  An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
BC Week In Review | Dec 16, 2013
Company News

Crealta Pharmaceuticals, Savient deal

Crealta will acquire Savient's pharmaceutical portfolio, including gout drug Krystexxa pegloticase, for about $120.4 million. The deal is the first for Crealta, which debuted in August to acquire specialty pharmaceutical companies and products that are...
BC Extra | Dec 12, 2013
Company News

Crealta to acquire Savient assets

Crealta Pharmaceuticals LLC (Lake Forest, Ill.) will acquire the pharmaceutical portfolio of Savient Pharmaceuticals Inc. (OTCQB:SVNTQ), including gout drug Krystexxa pegloticase, for about $120.4 million. The deal is the first for Crealta, which debuted in...
BC Week In Review | Oct 21, 2013
Company News

Savient, US WorldMeds endocrine/metabolic news

Savient filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. Savient also entered into an acquisition agreement with neurology company US WorldMeds and its subsidiary Sloan Holdings C.V. whereby...
BC Week In Review | Jul 1, 2013
Clinical News

Krystexxa pegloticase regulatory update

The U.K.'s NICE issued final guidance recommending against the use of Krystexxa pegloticase from Savient to treat severe chronic tophaceous gout in adult patients - its approved indication. The guidance is in line with a preliminary...
BC Week In Review | Jul 1, 2013
Company News

Savient endocrine/metabolic news

Savient formed an office of the president comprising three co-presidents to succeed Louis Ferrari, who is departing as CEO, president and a director. Savient will transition COO Richard Crowley to co-president from EVP; CFO John...
BC Week In Review | Jun 24, 2013
Company News

Savient sales and marketing update

Savient disclosed in an SEC filing that it raised the wholesale acquisition cost of gout drug Krystexxa pegloticase in the U.S. to $5,390 for an 8 mg/mL dose given every two weeks. The price, which...
BC Week In Review | May 20, 2013
Company News

Savient sales and marketing update

Savient said in its 1Q13 earnings that it raised the wholesale acquisition cost of gout drug Krystexxa pegloticase in the U.S. to $3,850 for an 8 mg/mL dose given every two weeks. The price, which...
Items per page:
1 - 10 of 258
BC Week In Review | Sep 1, 2014
Company News

Basilea management update

Basilea Pharmaceutica AG (SIX:BSLN), Basel, Switzerland   Business: Infectious, Dermatology, Cancer   Hired: David Veitch as chief commercial officer of Basilea’s Basilea Pharmaceutica International Ltd. subsidiary, formerly president of European operations at Savient Pharmaceuticals Inc....
BC Week In Review | Jan 20, 2014
Company News

Crealta Pharmaceuticals, Savient deal

Crealta completed its acquisition of Savient's pharmaceutical portfolio, including gout drug Krystexxa pegloticase, for about $120.4 million (see BioCentury, Dec.16, 2013). Crealta Pharmaceuticals LLC , Lake Forest, Ill.   Savient Pharmaceuticals Inc. (OTCQB:SVNTQ), Bridgewater, N.J.  ...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer  An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
BC Week In Review | Dec 16, 2013
Company News

Crealta Pharmaceuticals, Savient deal

Crealta will acquire Savient's pharmaceutical portfolio, including gout drug Krystexxa pegloticase, for about $120.4 million. The deal is the first for Crealta, which debuted in August to acquire specialty pharmaceutical companies and products that are...
BC Extra | Dec 12, 2013
Company News

Crealta to acquire Savient assets

Crealta Pharmaceuticals LLC (Lake Forest, Ill.) will acquire the pharmaceutical portfolio of Savient Pharmaceuticals Inc. (OTCQB:SVNTQ), including gout drug Krystexxa pegloticase, for about $120.4 million. The deal is the first for Crealta, which debuted in...
BC Week In Review | Oct 21, 2013
Company News

Savient, US WorldMeds endocrine/metabolic news

Savient filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. Savient also entered into an acquisition agreement with neurology company US WorldMeds and its subsidiary Sloan Holdings C.V. whereby...
BC Week In Review | Jul 1, 2013
Clinical News

Krystexxa pegloticase regulatory update

The U.K.'s NICE issued final guidance recommending against the use of Krystexxa pegloticase from Savient to treat severe chronic tophaceous gout in adult patients - its approved indication. The guidance is in line with a preliminary...
BC Week In Review | Jul 1, 2013
Company News

Savient endocrine/metabolic news

Savient formed an office of the president comprising three co-presidents to succeed Louis Ferrari, who is departing as CEO, president and a director. Savient will transition COO Richard Crowley to co-president from EVP; CFO John...
BC Week In Review | Jun 24, 2013
Company News

Savient sales and marketing update

Savient disclosed in an SEC filing that it raised the wholesale acquisition cost of gout drug Krystexxa pegloticase in the U.S. to $5,390 for an 8 mg/mL dose given every two weeks. The price, which...
BC Week In Review | May 20, 2013
Company News

Savient sales and marketing update

Savient said in its 1Q13 earnings that it raised the wholesale acquisition cost of gout drug Krystexxa pegloticase in the U.S. to $3,850 for an 8 mg/mL dose given every two weeks. The price, which...
Items per page:
1 - 10 of 258